A newly independent MedTech franchise with sticky, recurring revenue—priced like a troubled spin—where ERP execution and cost-out determine the re-rating.
Overview
Solventum (SOLV) is a newly independent, global healthcare company spun from 3M on April 1, 2024, with a long innovation heritage and a portfolio embedded in everyday clinical workflows. It serves 100,000+ customers across 90+ countries and generates roughly $8.3B of annual revenue with a strong recurring mix driven by consumables and software. The business is diversified across four segments: (1) Medical Surgical (~58% of sales) with brands like Tegaderm and Prevena; (2) Dental Solutions (~16%) anchored by high-margin daily-use consumables and orthodontics; (3) Health Information Systems (~16%) led by the widely deployed 360 Encompass platform moving toward AI autonomous coding; and (4) a smaller water filtration/other segment after divesting biopharma filtration to Thermo Fisher. Post-spin, Solventum is executing a multi-year transformation to modernize systems, reduce costs, specialize commercial teams, pay down debt, and return capital—setting up a potential valuation re-rating if execution holds.